Showing results (41-50 of 51) with videos related to
Sort By:
Pageof 6
Melanoma Research|June 21, 2019
Recurrence risk of early-stage melanoma of the external ear: an investigation of surgical approach and sentinel lymph node statusAmanda Truong, John R Hyngstrom, Robert H I Andtbacka, et al.Oncotarget|July 9, 2016
A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanomaAbhijit Ray, Matthew A Williams, Stephanie M Meek, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2017
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable MelanomaJason Chesney, Igor Puzanov, Frances Collichio, et al.Annals of Surgical Oncology|October 31, 2006
Surgical resection of gastrointestinal stromal tumors after treatment with imatinibRobert H I Andtbacka, Chaan S Ng, Courtney L Scaife, et al.Melanoma Research|August 12, 2017
Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysisLaura J Gardner, Morgan Ward, Robert H I Andtbacka, et al.Annals of Surgical Oncology|February 28, 2021
A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary AnalysisTimothy J Vreeland, Guy T Clifton, Diane F Hale, et al.Plos One|September 8, 2017
SCF-KIT signaling induces endothelin-3 synthesis and secretion: Thereby activates and regulates endothelin-B-receptor for generating temporally- and spatially-precise nitric oxide to modulate SCF- and or KIT-expressing cell functionsLei L Chen, Jing Zhu, Jonathan Schumacher, et al.Cell|September 9, 2017
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 ImmunotherapyAntoni Ribas, Reinhard Dummer, Igor Puzanov, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2020
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent MelanomaAlain P Algazi, Christopher G Twitty, Katy K Tsai, et al.Cancer Discovery|March 12, 2021
Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory MelanomaCara Haymaker, Daniel H Johnson, Ravi Murthy, et al.Pageof 6